Pneumocystosis
ICD-10 B71 is a billable code used to indicate a diagnosis of pneumocystosis.
Pneumocystosis, also known as Pneumocystis pneumonia (PCP), is a serious infection caused by the fungus Pneumocystis jirovecii. This organism is an opportunistic pathogen that primarily affects immunocompromised individuals, particularly those with HIV/AIDS, cancer, or those undergoing immunosuppressive therapy. The infection is characterized by a range of respiratory symptoms, including cough, fever, and difficulty breathing. Diagnosis is typically made through clinical evaluation, imaging studies such as chest X-rays or CT scans, and laboratory tests including bronchoalveolar lavage or induced sputum analysis. Treatment usually involves the use of antiparasitic medications such as trimethoprim-sulfamethoxazole (TMP-SMX), which is the first-line therapy. In cases of severe disease or intolerance to TMP-SMX, alternative treatments may include pentamidine or atovaquone. Early recognition and treatment are crucial to improving outcomes, as untreated pneumocystosis can lead to significant morbidity and mortality.
Detailed patient history, including immunocompromised status and treatment response.
Patients with HIV/AIDS presenting with respiratory symptoms.
Ensure that all laboratory results and imaging studies are clearly documented.
Thorough documentation of respiratory symptoms and diagnostic imaging findings.
Patients with unexplained pneumonia who are immunocompromised.
Document any differential diagnoses considered during evaluation.
Used to assess lung function in patients with suspected pneumocystosis.
Document the reason for testing and any relevant clinical findings.
Pulmonologists should ensure that the tests are linked to the diagnosis.
The primary treatment for pneumocystosis is trimethoprim-sulfamethoxazole (TMP-SMX), which is effective in managing the infection. Alternative treatments may be considered in cases of intolerance or severe disease.
